Pharma channel feed – Endpoints News

Pharma channel feed

Gilead gets a blockbuster boost from an FDA OK of HIV triplet Biktarvy — and rival GSK fires back

8 years ago

Verastem takes AbbVie’s blood cancer castoff to the FDA

8 years ago

J&J antes up on a $1B gamble that Theravance has the next blockbuster JAK for Crohn’s, ulcerative colitis

8 years ago

Zogenix wins inside track at FDA with childhood epilepsy ‘breakthrough’

8 years ago

The Endpoints 100: Biotech execs stampede into 2018 with a cheer for the FDA and bullish feelings on public markets, private investors and a ‘hot’ M&A future

8 years ago

Slammed by a trial hold, Intarcia terminates studies and axes staff in wake of an FDA rejection

8 years ago

Amgen’s $70B in ‘deal capacity’ post-tax reform puts the spotlight on 'big things' in M&A — analyst

8 years ago

AstraZeneca sweeps out a PhIII asthma flop, a PD-1 drug and some other rejects as Q4 tally disappoints

8 years ago

After EMA flop, Puma takes Nerlynx to China in new out-licensing deal

8 years ago

Nuclear scare to fuel anti-radiation drug sales? PTx buys ex-Sanofi drug just in case

8 years ago

Counting its remaining cash, Vical axes 40 staffers and circles wagons around two Phase II assets

8 years ago

Eyeing a multibillion-dollar market, Shire snags preclinical IVIg rival from AB Biosciences

8 years ago

Suspicious returns trigger insider trading suit following $11.6B Bioverativ deal

8 years ago

Roche scores an unusual ‘breakthrough’ at the FDA for an autism drug

8 years ago

In post-IPO party, Nasdaq’s newcomers Armo, Menlo and Solid soar within hours of listing

8 years ago

Novartis scores a quick FDA OK for its new cancer drug Lutathera, picked up in $4B buyout

8 years ago

Under pressure to perform, Woodford counterattacks against Sahm Adrangi's latest short assault

8 years ago

Biogen makes a buyout deal, but it’s not the big one you’ve been waiting for

8 years ago

Novartis steps in to grab ex-US rights to pioneering gene therapy Luxturna with $170M deal

8 years ago

Pfizer’s latest copycat could put the squeeze on Roche — again

8 years ago

Puma Biotechnology shares tank after CHMP looks ready to hit a red light on neratinib

8 years ago

J&J’s move to cut Remicade price cost some big bucks, but guarded against Pfizer’s copycat

8 years ago

FDA slaps down Braeburn on opioid addiction drug, putting Indivior and Alkermes in strong position

8 years ago

Government shutdown to end - at least temporarily - as Dems take McConnell at his word

8 years ago

First page Previous page 304 305 306307308 309 310 Next page Last page